News

The company plans to put up a total of more than 94 million shares—with about 10% offered in Hong Kong and the remainder placed internationally—priced at 24.05 per share in Hong Kong dollars, or about $3.09 U.S. apiece. The IPO—scheduled to run through Dec. 23, with trading starting Dec. 30—will wrap up a year that saw Insilico raise $110 million through a March venture capital round and ink multiple R&D deals with global drugmakers, including a recent pact with Eli Lilly potentially worth more than $100 million. This past February, Insilico published benchmarking timelines from 22 of its AI-designed drug candidates, which on average took about 13 months from the initial building of a large library of potential molecules through the whittling down to a chosen few for synthesis, testing and finally selection for clinical trials. In its prospectus (PDF) filed with the Hong Kong exchange, the company reported $85.8 million in revenue for the 2024 calendar year, with a net loss of $17.4 million.